Year: 2021

CURR News Update & More

CURE Pharmaceutical Holding Corp. (OTCMKTS:CURR)

We’re looking back in on CURR this morning on the heels of a key PR released by the company that we would like to share with our readers. We have been following this stock for roughly a month, and this FDA IND approval news is by far the most exciting development yet.

CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness space, announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for its product CUREfilm Blue™, an oral soluble film of sildenafil citrate (the active ingredient present in Viagra®1) for the treatment of erectile dysfunction (ED). CURE is seeking approval of this product via the 505(b)(2) regulatory pathway to expedite the U.S. approval process. (>>View Full PR via OTCMARKETS)

In addition to familiarizing yourself with the company’s news update, we would recommend you take a couple of minutes to check out the video presentation of the CURR chart that we have provided below: 


______

Please direct any investor inquiries on CURR to:

Gary Zwetchkenbaum
Plum Tree Consulting LLC
Phone: (718) 224-3123
Cell: (516) 455-7662
Website: www.plumtreeconsultingllc.com

Fresh Options Ideas:
SPY 01/06 $368-367 Puts

Extended Watchlist: 
TSPG, WDLF, ISWH, USRM, OZSC, LBRMF

Unique Money-Making Opportunity in 2021!

New Year, New Opportunities! 

We’ve got a new product offering coming in 2021 that we’re very excited about. We’ve had a lot of interest from members and contacts in a paid subscription that will offer a whole new level of detail over our daily premarket reports.

Beginning and intermediate traders alike will be the first who should take notice of this opportunity to learn from a seasoned veteran stock trader who’s been in the markets for nearly twenty years! In addition to conducting regular online classes detailing the intricacies of making big money using smart, risk-limiting tactics, subscribers will have access to a private chat and an ongoing stream of shrewd ideas.

Rest assured that our daily reports will continue to provide some of the best stock and options plays completely free as we have for the past ten years, but traders who are looking for a more hands-on approach to learning, and having access to a direct line to a true expert, are going to want to consider a subscription to this new elite-level service.

The inaugural class will be limited in size, so interested parties should contact us immediately in order to secure a place. Dozens of participants have already signed up, and we may have to close off enrollment as soon as this week! Don’t let this huge opportunity pass you by in 2021!

Call (585) 703-6565 today to learn more and secure your spot on the maiden voyage of our premium service!

Fresh Options Ideas:
MARA Weekly $11-12 Calls
RIOT Weekly $17-19 Calls 

Extended Watchlist: 
BTBT, MGTI, BTCS, XALL, HVBTF, RDAR, LUVU, PMPG